XIAP and breast carcinoma: On the basis of our clinico-pathological observations, we hypothesized that co-targeting of both PARP and XIAP might be an affective therapeutic target in treating aggressive BC and might extend the utility of olaparib beyond BRCA mutant breast cancer patients.